The selective butyrylcholinesterase inhibitor UW‐MD‐95 shows symptomatic and neuroprotective effects in a pharmacological mouse model of Alzheimer's disease - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Access content directly
Journal Articles CNS Neuroscience & Therapeutics Year : 2024

The selective butyrylcholinesterase inhibitor UW‐MD‐95 shows symptomatic and neuroprotective effects in a pharmacological mouse model of Alzheimer's disease

Abstract

Aims Alzheimer's disease (AD) is a devastating dementia characterized by extracellular amyloid‐β (Aβ) protein aggregates and intracellular tau protein deposition. Clinically available drugs mainly target acetylcholinesterase (AChE) and indirectly sustain cholinergic neuronal tonus. Butyrylcholinesterase (BChE) also controls acetylcholine (ACh) turnover and is involved in the formation of Aß aggregates and senile plaques. UW‐MD‐95 is a novel carbamate‐based compound acting as a potent pseudo‐irreversible BChE inhibitor, with high selectivity versus AChE, and showing promising protective potentials in AD. Methods We characterized the neuroprotective activity of UW‐MD‐95 in mice treated intracerebroventricularly with oligomerized Aβ 25‐35 peptide using behavioral, biochemical, and immunohistochemical approaches. Results When injected acutely 30 min before the behavioral tests (spontaneous alternation in the Y‐maze, object recognition, or passive avoidance), UW‐MD‐95 (0.3‐3 mg/kg) showed anti‐amnesic effects in Aβ 25‐35 ‐treated mice. When injected once a day over 7 days, it prevented Aβ 25‐35 ‐induced memory deficits. This effect was lost in BChE knockout mice. Moreover, the compound prevented Aβ 25‐35 ‐induced oxidative stress (assessed by lipid peroxidation or cytochrome c release), neuroinflammation (IL‐6 and TNFα levels or GFAP and IBA1 immunoreactivity) in the hippocampus and cortex, and apoptosis (Bax level). Moreover, UW‐MD‐95 significantly reduced the increase in soluble Aβ 1‐42 level in the hippocampus induced by Aβ 25‐35 . Conclusion UW‐MD‐95 appeared as a potent neuroprotective compound in the Aβ 25‐35 model of AD, with potentially an impact on Aβ 1‐42 accumulation that could suggest a novel mechanism of neuroprotection.
Fichier principal
Vignette du fichier
2024-CNS-30-e14814.pdf (4.02 Mo) Télécharger le fichier
Origin Publisher files allowed on an open archive
Licence

Dates and versions

hal-04628744 , version 1 (28-06-2024)

Licence

Identifiers

Cite

Allison Carles, Matthias Hoffmann, Matthias Scheiner, Lucie Crouzier, Christelle Bertrand‐gaday, et al.. The selective butyrylcholinesterase inhibitor UW‐MD‐95 shows symptomatic and neuroprotective effects in a pharmacological mouse model of Alzheimer's disease. CNS Neuroscience & Therapeutics, 2024, 30 (6), pp.e14814. ⟨10.1111/cns.14814⟩. ⟨hal-04628744⟩
71 View
18 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More